SCHEMBL6777970

SCHEMBL6777970

Cc1c(I)cc(Br)cc1C(=O)O

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
AKR1C3 P42330 3/20 0.47
AKR1C2 P52895 2/20 0.47
AKR1C1 Q04828 2/20 0.47
AKR1C4 P17516 1/20 0.47
HSD17B10 Q99714 1/20 0.46
KDM4E B2RXH2 2/20 0.46
MEN1 O00255 2/20 0.46
KMT2A Q03164 2/20 0.46
TDP1 Q9NUW8 1/20 0.46
MYC P01106 1/20 0.42
NR4A1 P22736 1/20 0.42
GLA P06280 1/20 0.41
RXFP1 Q9HBX9 1/20 0.38
EPRS1 P07814 2/20 0.37
LCK P06239 1/20 0.36
FYN P06241 1/20 0.36
SORT1 Q99523 2/20 0.36
METAP2 P50579 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27556655 0.85 AKR1C3 (0.56) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL600598 0.80 KDM4E (0.66) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
Bromobenzene SCHEMBL27997726 0.80 AKR1C3 (0.51) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL32686518 0.79 SLC6A3 (0.41) HSD17B10KDM4ERXFP1
SCHEMBL21200015 0.79 SLC6A3 (0.41) HSD17B10KDM4ERXFP1
SCHEMBL29548189 0.79 AKR1C3 (0.50) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL16652911 0.79 KDM4E (0.44) HSD17B10KDM4EMEN1KMT2ATDP1
SCHEMBL1071109 0.79 AKR1C3 (0.50) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL2226763 0.79 AKR1C3 (0.61) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10
SCHEMBL3361120 0.78 AKR1C3 (0.53) AKR1C3AKR1C2AKR1C1AKR1C4HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6831199-B1 In order to avoid bleeding side-effects when treating the conditions associated with integrin alpha v beta 3, it is beneficial to have compounds which are selective antagonists for alpha v beta 3 versus alpha IIb beta 3 G. D. SEARLE & CO. 2004-12-14 US disclosed
EP-0850221-B1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS SEARLE & CO (US) 2001-07-18 EP disclosed
US-6028223-A AN INTEGRIN ANTAGONISTS TREATING BONE DISORDER, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR ANGIOGENESIS, DIABETIC RETINOPATHY, ARTHRITIS, SMOOTH MUSCLE CELL MIGRATION AND RESTENOSIS G. D. SEARLE & CO. (US) 2000-02-22 US disclosed
EP-0850221-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1998-07-01 EP disclosed
WO-1997008145-A1 META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS G.D. SEARLE & CO. (US) 1997-03-06 WO disclosed